Collaboration and Licensing Agreement
DXS INTERNATIONAL PLC
Continued here:
Collaboration and Licensing Agreement
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated…
Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29, iv192iv237 (2018).
CAS PubMed Google Scholar
Ettinger, D. S. et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, 2020. J. Natl. Compr. Canc. Netw. 17, 14641472 (2019).
PubMed Google Scholar
Aggarwal, C. et al. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat. Rev. Clin. Oncol. 18, 5662 (2021).
PubMed Google Scholar
Kunimasa, K. et al. Improvement strategies for successful next-generation sequencing analysis of lung cancer. Future Oncol. 16, 15971606 (2020).
CAS PubMed Google Scholar
Leighl, N. B. et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 46914700 (2019).
CAS PubMed Google Scholar
Saarenheimo, J., Andersen, H., Eigeliene, N. & Jekunen, A. Gene-guided treatment decision-making in non-small cell lung cancerA systematic review. Front. Oncol. 11, 754427 (2021).
PubMed PubMed Central Google Scholar
Rolfo, C. et al. Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 16, 16471662 (2021).
CAS PubMed Google Scholar
Laufer-Geva, S. et al. The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer. J. Thorac. Oncol. 13, 17051716 (2018).
PubMed Google Scholar
Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15, e0237802 (2020).
CAS PubMed PubMed Central Google Scholar
Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548554 (2014).
CAS PubMed PubMed Central Google Scholar
Kukita, Y. et al. High-fidelity target sequencing of individual molecules identified using barcode sequences: De novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients. DNA Res. 22, 269277 (2015).
CAS PubMed PubMed Central Google Scholar
Casbon, J. A., Osborne, R. J., Brenner, S. & Lichtenstein, C. P. A method for counting PCR template molecules with application to next-generation sequencing. Nucl. Acids Res. 39, e81 (2011).
CAS PubMed PubMed Central Google Scholar
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U.S.A. 108, 95309535 (2011).
ADS PubMed PubMed Central Google Scholar
Akahori, D. et al. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. Sci. Rep. 11, 14999 (2021).
CAS PubMed PubMed Central Google Scholar
Takada, R. et al. Clinical utility of pancreatic cancer circulating tumor DNA in predicting disease progression, prognosis, and response to chemotherapy. Pancreas 49, e93e95 (2020).
CAS PubMed Google Scholar
Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646650 (1977).
CAS PubMed Google Scholar
Mouliere, F. et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS ONE 6, e23418 (2011).
ADS CAS PubMed PubMed Central Google Scholar
Yamamoto, Y. et al. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci. 110, 617628 (2019).
CAS PubMed PubMed Central Google Scholar
Liu, X. et al. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. EBioMedicine 41, 345356 (2019).
PubMed PubMed Central Google Scholar
Underhill, H. R. et al. Fragment length of circulating tumor DNA. PLoS Genet. 12, e1006162 (2016).
PubMed PubMed Central Google Scholar
Liu, Y. et al. Increased detection of circulating tumor DNA by short fragment enrichment. Transl. Lung Cancer Res. 10, 15011511 (2021).
CAS PubMed PubMed Central Google Scholar
Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aat4921 (2018).
Article PubMed PubMed Central Google Scholar
Underhill, H. R. Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: A pathway to advanced non-invasive diagnostics in precision oncology?. Mol. Diagn. Ther. 25, 389408 (2021).
CAS PubMed PubMed Central Google Scholar
Li, F. et al. Ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients. Cancers (Basel) 12, 2041 (2020).
CAS Google Scholar
Heitzer, E., Auinger, L. & Speicher, M. R. Cell-free DNA and apoptosis: How dead cells inform about the living. Trends Mol. Med. 26, 519528 (2020).
CAS PubMed Google Scholar
Jahr, S. et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 16591665 (2001).
CAS PubMed Google Scholar
Jensen, T. J. et al. Whole genome bisulfite sequencing of cell-free DNA and its cellular contributors uncovers placenta hypomethylated domains. Genome Biol. 16, 78 (2015).
PubMed PubMed Central Google Scholar
Udomruk, S., Orrapin, S., Pruksakorn, D. & Chaiyawat, P. Size distribution of cell-free DNA in oncology. Crit. Rev. Oncol. Hematol. 166, 103455 (2021).
PubMed Google Scholar
Park, S. et al. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Cancer 127, 30193028 (2021).
CAS PubMed Google Scholar
Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A. & Anker, P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313, 139142 (2001).
CAS PubMed Google Scholar
Wang, B. G. et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 63, 39663968 (2003).
CAS PubMed Google Scholar
Avanzini, S. et al. A mathematical model of ctDNA shedding predicts tumor detection size. Sci. Adv. https://doi.org/10.1126/sciadv.abc4308 (2020).
Article PubMed PubMed Central Google Scholar
Ying, H. Q. et al. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. Pharmacol. Res. 170, 105734 (2021).
CAS PubMed Google Scholar
Chen, Y. M. et al. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 16, 868 (2016).
CAS PubMed PubMed Central Google Scholar
Garrido, P. et al. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med. 10, 58785888 (2021).
CAS PubMed PubMed Central Google Scholar
Sueoka-Aragane, N. et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Med. 10, 38733885 (2021).
CAS PubMed PubMed Central Google Scholar
Sakai, K. et al. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Mol. Oncol. 15, 126137 (2021).
CAS PubMed Google Scholar
Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629640 (2017).
CAS PubMed Google Scholar
Papadimitrakopoulou, V. A. et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 31, 15361544 (2020).
CAS PubMed Google Scholar
Oxnard, G. R. et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 4, 15271534 (2018).
PubMed Google Scholar
Wang, F. et al. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut 71, 13401349 (2021).
PubMed Google Scholar
Shaw, A. T. et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374, 5461 (2016).
CAS PubMed Google Scholar
Blakely, C. M. et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat. Genet. 49, 16931704 (2017).
CAS PubMed PubMed Central Google Scholar
Mouliere, F. et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol. Med. 13, e12881 (2021).
CAS PubMed PubMed Central Google Scholar
Nagai, Y. et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65, 727682 (2005).
CAS PubMed Google Scholar
Kukita, Y. et al. Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter. PLoS ONE 13, e0192611 (2018).
PubMed PubMed Central Google Scholar
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 17541760 (2009).
CAS PubMed PubMed Central Google Scholar
Koboldt, D. C. et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568576 (2012).
CAS PubMed PubMed Central Google Scholar
Kukita, Y. et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS ONE 8, e81468 (2013).
ADS PubMed PubMed Central Google Scholar
Cao, Y., Xie, L., Xie, Y. & Xu, H. Sequential change-point detection via online convex optimization. Entropy 20, 108 (2018).
ADS PubMed Central Google Scholar
This breakthrough stem-cell therapy could reverse genetic blindness – Inverse
A promising method to treat blindness is to implant healthy light-sensitive cells into failing eyes. But these cell therapies which have been in development for at least three decades often fail because the implanted cells die rapidly or fail to incorporate themselves into the eyes. But new stem-cell research could potentially eliminate these roadblocks.
Whats new Experiments with human stem cells and dogs reveal that a cocktail of drugs that suppress the immune system could help implanted cells survive for months. In fact, the implanted cells even began integrating with the eyes, according to a new study published in the journal Stem Cell Reports.
The scientists injected immunosuppressed dogs with advanced stages of inherited retinal degeneration with the precursors to photoreceptor cells coaxed from human stem cells. They found that the immature cells developed into full-grown photoreceptors and that they started to form connections with the dogs neurons. The research offers a critical first step toward using stem-cell therapies to treat eye conditions, including inherited forms of blindness.
HERE'S THE BACKGROUND Genetic cases of blindness often result from problems with the light-sensitive rod and cone cells in the retina, the tissue that lines the inner eyeball. Scientists have had great success in treating some genetic eye conditions using gene therapies, which involve injecting working versions of malfunctioning genes into the eyes photoreceptor cells. But the genes responsible for many genetic cases of blindness remain unknown.
In turn, several forms of genetic blindness have no gene therapy or indeed any therapeutic options. And for some people it is already too late their condition has progressed so far that no photoreceptor cells remain intact, so gene therapy wouldnt have an effect anyway. Instead, regenerative therapies to replace ailing photoreceptors with functional cells could offer another avenue to reversing blindness.
How they did it In the new study, researchers dosed human stem cells with chemicals that coaxed them into forming the precursors of photoreceptor cells. To help track these cells positions over time, the stem cells were genetically modified to generate fluorescent proteins.
The scientists then injected them into the retinas of seven dogs with normal vision and three with advanced stages of inherited retinal degeneration. In the animals, these immature cells matured into photoreceptors.
When the stem cells were injected into the dogs with normal vision, their retinas were still intact, and therefore served as physical barriers that prevented the implanted cells from connecting with neurons in the eyes. But in the dogs with retinal degeneration (for which the treatment is targeted) the injected cells did a much better job migrating into the retina.
Since the canines immune systems would likely recognize the transplanted human cells as foreign entities and attack them, the researchers gave some immunosuppressive drugs.
As expected, injected cell numbers declined substantially in the canines who did not receive the drug cocktail, whereas cell numbers dipped but then kept steady in dogs who did receive the drugs. The cells in the immunosuppressed dogs survived up to five months post-injection. The researchers also detected signs of implanted cells connecting with neurons in the pups eyes.
Its challenging to turn stem cells into photoreceptors and ensure theyre fully integrated into the eye, but researchers hope patients own cells can eventually be used to treat blindness while avoiding adverse immune reactions.dra_schwartz/E+/Getty Images
Why it matters Discovering that human photoreceptor precursor cells could survive and mature into photoreceptor cells after being transplanted into an adult canine retina suggests regenerating a specific layer of the retina the one that contains rod and cone photoreceptors is possible in an adult eye.
This provides hope for being able to treat patients even in adulthood, Beltran says.
Importantly, the dogs used in this study also provide a better picture of how the same therapy might work in humans. Senior study author William Beltran, a veterinary ophthalmologist and vision scientist at the University of Pennsylvania, tells Inverse that dogs are good models for humans in this case for several reasons, ostensibly making translating the research into human bodies later a simpler task.
For one, large animal models with human-size eyes allow scientists to develop the same surgical approaches that may be used in people.
Dogs also receive therapy doses akin to those that would most likely be used in people, and they may experience some of the same immune reactions as we do.
WHAT'S NEXT In the future, the researchers will continue to refine their technique and eventually test whether the dogs experience improved vision due to the implanted cells.
Its still unclear why some implanted cells died within a few days following transplantation even when dogs were given immunosuppressive drugs. The team is investigating this process in hopes that they can try to improve graft survival, Beltran says.
All in all, future cell therapies for retinal degeneration may require immunosuppressive drugs if the donor cells arent genetically identical to the recipient. The best approach to prevent adverse immune reactions without using immunosuppressive drugs would be to inject stem-cell-derived photoreceptors from the patient after theyve been corrected for genetic defects, Beltran says.
Treatments for blindness may soon join the rapidly expanding and extremely expensive category of personalized medicine.
More like this
Some people with epilepsy find relief with CBD but the market is murky
By Kaiser Health News and Eric Berger
This genetically modified rice could transform the global food supply
By Joanna Thompson
This popular anti-aging goo can help regrow muscle study
By Miriam Fauzia
LEARN SOMETHING NEW EVERY DAY.
Original post:
This breakthrough stem-cell therapy could reverse genetic blindness - Inverse
Stem Cell Membrane-Coated Nanoparticles in Tumor Therapy – AZoNano
Cell membrane-coated nanoparticles, applied in targeted drug delivery strategies, combine the intrinsic advantages of synthetic nanoparticles and cell membranes. Although stem cell-based delivery systems were highlighted for their targeting capability in tumor therapy, inappropriate stem cells may promote tumor growth.
Study:Stem cell membrane-camouflaged targeted delivery system in tumor. Image Credit:pinkeyes/Shutterstock.com
A review published in the journalMaterials Today Biosummarized the role of stem cell membrane-camouflaged targeted delivery system in tumor therapy and focused on the underlying mechanisms of stem cell homing toward target tumors. Nanoparticle-coated stem cell membranes have enhanced targetability, biocompatibility, and drug loading capacity.
Furthermore, the clinical applications of induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) were investigated as membrane-camouflaged targeted delivery systems for their anti-tumor therapies. In concurrence, the stem cell membrane-coated nanoparticles have immense prospects in tumor therapy.
Cell-based targeted delivery systems have low immunogenicity and toxicity, innate targeting capability, ability to integrate receptors, and long circulation time. Cells such as red blood cells, platelets, stem cells, tumor cells, immune cells, and even viral/bacterial cells can serve as effective natural vesicles.
MSCs derived from the umbilical cord (UC-MSCs), bone marrow (BM-MSCs), and adipose tissue (ATMSCs) are utilized in clinical applications. However, iPSCs are preferable over MSCs in clinical applications due to their easy fetch by transcription factor-based reprogramming of differentiation of somatic cells.
Stem cells (MSCs/ iPSCs) can be easily isolated and used as drug delivery systems for tumor therapy. Stem cell-based delivery systems have inflammation or tumor lesions targeting capacity. However, stem cells are often entrapped in the lung due to their size, resulting in microembolism.
Cell membrane-coated nanoparticles are applied in targeted delivery strategies. To this end, stem cell membrane-coated nanoparticles have tremendous prospects in biomedical applications. Although previous reports mentioned the role of cell membrane-coated nanocarriers in tumor therapy, delivery systems based on stem cell membranes have not been explored extensively.
Stem cell membrane-coated nanoparticles obtained from stem cells have complex functioning and can achieve biological interfacing. Consequently, stem cell membrane-coated nanoparticles served as novel drug delivery systems that could effectively target the tumor.
Previous reports mentioned the preparation of doxorubicin (DOX) loaded, poly (lactic-co-glycolic acid) (PLGA) coated MSC membrane-based nanovesicles, which showed higher cellular uptake than their PLGA uncoated counterparts. Similarly, the DOX-loaded MSC membrane-coated gelatin nanogels showed enhanced storage stability and sustained drug release.
Thus, the stem cell membrane-coated nanoparticles served as novel carriers for stem cells and facilitated the targeted delivery of the drugs at the tumor site. Since the stem cell membrane-coated nanoparticles had good targeting and penetration abilities, they enhanced the efficiency of chemotherapeutic agents in tumor therapy and minimized the side effects.
Reactive oxygen species (ROS) based photodynamic therapy (PDT) is mediated by photosensitizers with laser irradiations. Previous reports mentioned the development of MSC membrane-based mesoporous silica up-conversion ([emailprotected]2) nanoparticles that efficiently targeted the tumor due to their high affinity after being coated with MSC membrane.
These cell membrane-coated nanoparticles showed high cytocompatibility (with hepatocyte cells) and hemocompatibility (with blood). Moreover, the [emailprotected]2 nanoparticles-based PDT therapy under 980-nanometer laser irradiations could inhibit the tumors in vivo and in vitro. Consequently, the stem cell membrane-coated nanoparticles had circulation for an extended time and escaped the immune system, thereby increasing their accumulation at the tumor site.
Stem cell membrane-coated nanoparticles were also applied to deliver small interfering RNA (siRNA) via magnetic hyperthermia therapy and imaging. Previous reports mentioned the preparation of superparamagnetic iron oxide (SPIO) nanoparticles using an MSC membrane that reduced the immune response.
Additionally, the CD44 adhesion receptors were preserved on the surface of the MSC membrane during preparation. These prepared nanovesicles were unrecognized by macrophages, which enabled their stability in blood circulation. The nanosize and tumor homing capacity of MSCs helped the nanovesicles generate a dark contrast in T2-weight magnetic resonance imaging (MRI).
Cell membrane-coated nanoparticles helped fabricate various targeted delivery strategies. Especially, stem cell membrane-coated nanoparticles have the following advantages: stem cells are easy to isolate and expand in vitro. Thus, multilineage potential and phenotypes could be preserved for more than 50 population doublings in vitro.
Stem cell membrane-coated nanoparticles also have an intrinsic capacity to target inflammation or tumor lesions. Hence, these nanoparticles were established for tumor therapy, building a strong foundation for stem cell membrane-mediated delivery systems.
On the other hand, stem cell membrane-coated nanoparticles have the following drawbacks: Despite various sources for collecting MSCs (UC-MSCs/BM-MSCs/ATMSCs), the number of cells obtained is limited, although iPSCs are relatively easy to fetch by reprogramming differentiated somatic cells, the reprogramming is a high-cost step, restricting the clinical applications of iPSCs.
Zhang, W., Huang, X. (2022). Stem cell membrane-camouflaged targeted delivery system in tumor. Materials Today Bio.https://www.sciencedirect.com/science/article/pii/S2590006422001752
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.
See the original post here:
Stem Cell Membrane-Coated Nanoparticles in Tumor Therapy - AZoNano
Culture of human nasal olfactory stem cells and their extracellular vesicles as advanced therapy medicinal products – Newswise
Abstract: The olfactory ecto-mesenchymal stem cell (OE-MSC) are mesenchymal stem cells originating from the lamina propria of the nasal mucosa. They have neurogenic and immune-modulatory properties and showed therapeutic potential in animal models of spinal cord trauma, hearing loss, Parkinsons disease, amnesia, and peripheral nerve injury. In this paper we designed a protocol that meet the requirements set by human health agencies to manufacture these stem cells for clinical applications. Once purified, OE-MSCs can be used per se or expanded in order to get the extracellular vesicles (EV) they secrete. A protocol for the extraction of these vesicles was validated and the EV from the OE-MSC were functionally tested on an in vitro model. Nasal mucosa biopsies from three donors were used to validate the manufacturing process of clinical grade OE-MSC. All stages were performed by expert staff of the cell therapy laboratory according to aseptic handling manipulations, requiring grade A laminar airflow. Enzymatic digestion provides more rapidly a high number of cells and is less likely to be contaminated. Foetal calf serum was replaced with human platelet lysate and allowed stronger cell proliferation, with the optimal percentage of platelet lysate being 10%. Cultivated OE-MSCs are sterile, highly proliferative (percentage of CFU-F progenitors was 15,5%) and their maintenance does not induce chromosomal rearrangement (karyotyping and chromosomal microarray analysis were normal). These cells express the usual phenotypic markers of OE-MSC. Purification of the EVs was performed with ultracentrifugation and size exclusion chromatography. Purified vesicles expressed the recognized markers of EVs (Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines) and promoted cell differentiation and neurite elongation in a model of neuroblastoma Neuro2a cell line. We developed a safer and more efficient manufacturing process for clinical-grade olfactory stem cells, these cells can now be used in humans. A phase I clinical trial will begin soon. An efficient protocol for the purification of the OE-MSC EVs have been validated. These EVs exert neurogenic properties in vitro. More studies are needed to understand the exact mechanisms of action of these EVs and prove their efficacy and safety in animal models.
Follow this link:
Culture of human nasal olfactory stem cells and their extracellular vesicles as advanced therapy medicinal products - Newswise
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8 T Cells from TCR-CAR+ Induced Pluripotent Stem Cells -…
TCR-CAR+ iPSC-derived CD8 T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model
Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR-CAR+ iPSC-derived CD8 T Cells Compared Favorably with Healthy-donor Peripheral Blood CAR T Cells
Phase 1 Study Ongoing of First-ever iPSC-derived T-cell Product Candidate FT819 for Off-the-shelf Treatment of Patients with Relapsed / Refractory B-cell Malignancies
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. ( FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8 T cells from induced pluripotent stem cells (iPSCs). The CD8 T cells were derived from a single engineered iPSC integrating a novel chimeric antigen receptor (CAR) transgene into the T-cell receptor alpha constant (TRAC) locus, ensuring complete bi-allelic disruption of T-cell receptor (TCR) expression and promoting uniform CAR expression. The discoveries were made under a multi-year research collaboration between the Company and Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Head, Gene Expression and Gene Transfer Laboratory, and were published this week in Nature Biomedical Engineering.
Scientists have previously differentiated induced pluripotent stem cells to form CAR T cells, however, it was observed that premature TCR or constitutive CAR expression resulted in the derivation of innate-like T cells that do not acquire the phenotype nor exhibit the function of conventional CD8 T cells, said Dr. Sadelain. Our published findings are the first to show the generation of iPSC-derived CD8 CAR T cells lacking a TCR, where timed and calibrated expression of the CAR in place of the TCR successfully drove T-cell maturation and promoted the acquisition of a transcriptional and functional profile more closely resembling that of natural CD8 T cells.
The mass production of TCR-CAR+ CD8 T cells from master engineered iPSC lines is a promising approach for development of off-the-shelf, cell-based cancer immunotherapies. Through a systematic assessment of factors that affect T-cell lineage commitment and induce adaptive T-cell formation, the researchers discovered that integrating the CAR construct into the TRAC locus delayed its expression and drove T-cell lineage commitment, and that regulation of CAR signaling strength promoted the generation of CD4+CD8+ double-positive cells mimicking thymic development in the absence of a TCR. Subsequent stimulation of the CAR matured the double-positive population into single-positive CD8 T cells with a phenotype highly correlated with peripheral blood CD8 effector T cells and distinct from T cells and natural killer cells. Preclinical studies showed that iPSC-derived TCR-CAR+ CD8 T cells were able to repeatedly lyse tumor cells in vitro and durably control leukemia in vivo, with persistence in the bone marrow, spleen, and blood, in a systemic NALM6 leukemia model.
These published findings continue to support our unique ability to generate TCR-CAR+ CD8 T cells from master engineered iPSC lines that exhibit a phenotypic profile and anti-tumor activity comparable to healthy donor-derived peripheral blood CAR T cells in preclinical model systems, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. We believe our off-the-shelf, iPSC-derived CAR T cell programs overcome the numerous challenges associated with the manufacture, consistency, and reach of autologous and allogeneic CAR T cells, and we look forward to sharing initial clinical data from our landmark Phase 1 study of FT819 later this year.
The Company is conducting a multicenter Phase 1 study of FT819, the first T-cell therapy manufactured from a clonal master iPSC line to undergo clinical investigation. The product candidates clonal engineered master iPSC line is created from a single iPSC that has a novel CD19-targeted 1XX CAR construct integrated into the TRAC locus, ensuring complete bi-allelic disruption of TCR expression to prevent graft-versus-host disease and promoting uniform CAR expression for enhanced anti-tumor activity. Dose escalation is currently ongoing in single-dose and multi-dose escalation cohorts for relapsed / refractory B-cell malignancies.
Pursuant to a license agreement with MSK, Fate Therapeutics has an exclusive license for all human therapeutic use to U.S. Patent No. 10,370,452, which covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC. In addition to the patent rights licensed from MSK, the Company owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.
Fate Therapeutics has licensed intellectual property from MSK on which Dr. Sadelain is an inventor. As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.
About Fate Therapeutics iPSC Product Platform The Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that are designed to be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely designed to overcome numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
About FT819 FT819 is an investigational, universal, off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line, which is engineered with the following features designed to improve the safety and efficacy of CAR19 T-cell therapy: a novel 1XX CAR signaling domain, which has been shown to extend T-cell effector function without eliciting exhaustion; integration of the CAR19 transgene directly into the T-cell receptor alpha constant (TRAC) locus, which has been shown to promote uniform CAR19 expression and enhanced T-cell potency; and complete bi-allelic disruption of TCR expression for the prevention of graft-versus-host disease. FT819 demonstrated antigen-specific cytolytic activity in vitro against CD19-expressing leukemia and lymphoma cell lines comparable to that of primary CAR T cells, and persisted and maintained tumor clearance in the bone marrow in an in vivo disseminated xenograft model of lymphoblastic leukemia. FT819 is being investigated in a multicenter Phase 1 clinical trial for the treatment of relapsed / refractory B-cell malignancies, including B-cell lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia (NCT04629729).
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Companys progress, plans and timelines for the manufacture and clinical investigation of its product candidates, the Companys initiation and continuation of enrollment in its clinical trials including additional dose cohorts in ongoing clinical trials of its product candidates, the therapeutic and market potential of the Companys product candidates, and the Companys clinical development strategy, including for its product candidate FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Companys product candidates may not demonstrate the requisite safety or efficacy to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Companys product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Companys product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Companys product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Companys ongoing and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of FT819 may not be replicated in ongoing or future clinical trials, and the risk that FT819 may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [emailprotected]
Desperate long Covid sufferers are trying every therapy, from ozone treatment to stem cell infusion – Scroll.in
People with long Covid are going online to look for support. But these valuable discussion forums, chat groups and other online peer-support networks can also spread harmful misinformation.
Online groups allow unproven therapies to be promoted, sometimes by members who believe they are sharing helpful information. Sometimes entrepreneurs are promoting their unproven therapies directly.
Health researchers admit there are few evidence-based treatments for long Covid. In the face of such uncertainty, people with debilitating symptoms can be tempted by unproven options such as blood washing, stem cell infusions and ozone treatments.
Some despairing people with long Covid say they are willing to try any therapy if theres hope it improves their health.
People with long Covid can suffer debilitating health problems that make it difficult to return to work or activities they once enjoyed. Symptoms include fatigue, brain fog, chronic pain, depression and anxiety.
They have had to fight to receive medical attention or recognition of their symptoms. Indeed, it was patient-led activism that first made the public and health professionals aware how symptoms can extend for months, even after an initially mild Covid infection.
Online discussion forums such as Reddit, as well as networks on Facebook and Twitter, have made a major difference to the long Covid community.
In the face of a lack of medical knowledge about long Covid and sometimes denial it exists, these peer networks offer emotional support and share important information about symptoms and treatments.
Reddit has a forum with tens of thousands of members discussing supplements and treatments for long Covid. This approach has been called crowdsourced medicine.
However, there are pitfalls and potential dangers of this kind of online networking and crowdsourced medicine the potential for spreading misinformation.
This issue has been a problem for a long time, particularly with other contested illnesses the medical profession has often dismissed. These include the chronic pain condition fibromyalgia and myalgic encephalomyelitis (chronic fatigue syndrome).
Weve also seen the spread of health misinformation in online patient forums and social media content about earlier infectious diseases, such as Zika virus, as well as throughout the current pandemic on topics including masks and vaccines.
Medical science is attempting to research long Covid and find treatments, but this kind of research takes time.
Meanwhile, people wanting answers and help for their symptoms are forced to turn to online sources, where the testing and review of treatments are under far less expert scrutiny.
On Reddit and other sites, the volume of content members must somehow make sense of is overwhelming.
Individuals, doctors and pharmaceutical company representatives are among those who have promoted experimental therapies that have not been thoroughly tested with clinical trials.
Some individuals or groups are exploiting peoples desperation, using long Covid support networks to attempt to profit from offering treatment plans or alternative therapies such as vitamin supplements and ozone treatment.
Some long Covid groups are are still recommended drugs such as the now scientifically discredited Covid treatment ivermectin.
Some patients have spent large sums of money on dubious therapies. Serious ethical concerns are raised by these actions, including the potential for these therapies to cause harm and worsen peoples health.
People with long Covid
People with long Covid should carefully weigh any anecdotal recommendations about treatment they come across online and think twice before sharing it.
Some have suggested a code of conduct for long Covid support groups that prohibits members from recommending treatments while allowing them to discuss their own experiences. This could help limit the spread of false information. A code of conduct could also ban the promotion of for-profit treatment programs to remove the risk of members being scammed.
However, this would require close moderation and not all sites or social media groups have such resources.
Hunting down the source of information about long Covid treatments and seeing if theres any links to published scientific evidence is another way to exercise caution.
Health workers
There are important lessons for health-care providers in understanding the needs of people with long Covid.
This includes the importance of providing a timely diagnosis and access to up-to-date valid medical information as well as acknowledging the uncertainties and distress many people feel.
Partnering with patients by acknowledging their lived expertise and together working for a solution would go a long way to help people who feel unheard and want to play an active role in improving their health.
The medical profession is beginning to recognise these issues and has also begun to identify how a better understanding of long Covid could cast light on better recognition and treatment for other contested illnesses.
Deborah Lupton is SHARP Professor, leader of the Vitalities Lab, Centre for Social Research in Health and Social Policy Centre at UNSW Sydney, and leader of the UNSW Node of the ARC Centre of Excellence for Automated Decision-Making and Society at UNSW Sydney.
This article first appeared on The Conversation.
Cell Therapy Technologies Market worth $8.0 billion by 2027 – Exclusive Report by MarketsandMarkets – PR Newswire
CHICAGO, Aug. 3, 2022 /PRNewswire/ --Cell Therapy Technologies Marketis projected to grow from USD 4.0 billion in 2022 to USD 8.0 billion by 2027, at a CAGR of 14.6% from 2022 to 2027, according to a new report by MarketsandMarkets.Growth in the market can be attributed to number of cell therapy clinical trials related to cancer. Furthermore, increasing incidence of communicable diseases and the growing risk of pandemics are also expected to fuel the market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978
Browse in-depth TOC on "Cell Therapy Technologies Market"202 Tables48 Figures218 Pages
The cell therapy equipment segment accounted for the second largest share of the product segment in the cell therapy technologies market in 2021.
The second largest share of cell therapy equipment segment can be attributed to the growing demand for these equipments. Cell therapy equipment is used in cell processing (such as cell isolation, expansion, and harvesting), cell preservation and handling, and process monitoring and quality control. The segment market is further sub-segmented into cell processing equipment, single-use equipment, and other equipment (flow cytometers, cell counters, microscopes, etc).
The stem cells segment accounted for the second largest share of the cell type segment in the cell therapy technologies market in 2021.
Rising awareness regarding the use of stem cells in the treatment of various diseases and the growing focus of players on stem cell research are driving the growth of this market segment. Rising collaboration between universities and biotechnology & biopharmaceutical companies for stem cell research and government support (availability of funding) are other important drivers.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978
The Asia Pacific region is the fastest-growing region of the cell therapy technologies market in 2021.
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the market of the region is mostly driven by their low labor and manufacturing costs, which has drawn huge investments by biopharma giants to these countries. The increasing disposable income, growing prevalence of lifestyle and age-related chronic diseases also contribute to the high growth of the regional market.
Key players in the cell therapy technologies market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=213334978
Browse Adjacent Market: Biotechnology MarketResearch Reports & Consulting
Related Reports:
Cell Culture Marketby Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) - Global Forecast to 2026
About MarketsandMarkets
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Aashish MehraMarketsandMarkets INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-therapy-technologies-market.asp Visit Our Website: https://www.marketsandmarkets.com/ Content Source: https://www.marketsandmarkets.com/PressReleases/cell-therapy-technologies.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
SOURCE MarketsandMarkets
The rest is here:
Cell Therapy Technologies Market worth $8.0 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire
Blood Stem Cell Donation Know 8 Myths And Facts That You Need To Know – ABP Live
By Patrick Paul
A blood stem cell transplant is a lifesaving treatment for patients with blood cancer and other blood disorders like Thalassemia and Aplastic Anemia. In India, the burden of blood-related disorders is continuously rising with almost a lakh new cases of blood cancer every year. If patients suffering from life-threatening diseases receive timely treatment with matching potential blood stem cell donors, they can get a second chance at life.
In India, only 0.04% of the total population is registered as a potential blood stem cell donor which is significantly lower than many other countries including the US where 2.7% and Germany where 10% of the population is registered as a potential donor. Hence, the chances of finding a matching donor for Indian patients is as little as 10-15% in comparison to western countries where the chances are as high as 60-70%.
There are certain myths and misconceptions regarding the process of blood stem cell donation that often dont allow individuals to come forward and become a donor. Here are some of the most common myths:
Myth: Once you donate blood stem cells, you will lose them forever.
Fact: Only a fraction of total stem cells is extracted during the process. Also, all the cells are naturally replenished within a few weeks
Myth: Donating stem cells is a really invasive and painful process
Fact: Blood stem cells are collected through peripheral blood stem cell collection (PBSC) which is completely safe and a non-surgical procedure. The process is similar to blood platelet donation which takes approximately three to four hours to complete and the donor can leave the collection centre the same day.
Myth: Blood Donation and blood stem cell donation are the same
Fact: Unlike blood collection for transfusion, blood stem cells are collected only when there is a match between the donor and patients Human leukocyte antigen (HLA) combination (tissue type). So, you could be potentially the only match and Life Saver for a person with blood cancer in need of a transplant
Blood stem cell donors donate only blood stem cells and the process is similar to a platelet donation.
Myth: Pregnant women cant register
Fact: This is untrue, a woman can register even during her pregnancy.
Myth: Stem cell donation leaves prolonged side-effects
Fact: No, there are no major side effects post blood stem cell donation. A person may only experience minor flu-like symptoms because of the GCSF injections given to him/her before the donation, to mobilize blood stem cells in the bloodstream.
Myth: Piercing and/or tattoo is a restricting factor
Fact: Piercing or a tattoo doesnt stop you from registering yourself to be a potential donor.
Myth: My blood stem cells can be stored
Fact: Your blood stem cells will not be stored. They last for around 72 hours and are delivered to the recipient straight to the hospital by a special courier. If the recipients body accepts them, the stem cells will start making healthy blood cells.
Myth: Joining a blood stem cell registry is no use. Most patients can find a stem cell donor within their own families.
Fact: Per statistics, only 30% of blood disorder patients in need of a stem cell transplant are able to find a sibling match. About 70% of patients need an unrelated donor.
India is a data bank of potential blood stem cell donors that houses details on thousands of committed blood stem cell donors. Any patient can benefit from this registry provided an HLA match.
The author is the CEO of DKMS BMST Foundation India
Check out below Health Tools- Calculate Your Body Mass Index ( BMI )
Calculate The Age Through Age Calculator
Continued here:
Blood Stem Cell Donation Know 8 Myths And Facts That You Need To Know - ABP Live
Way Research collaborates with UPM on cure for breast cancer – The Edge Markets MY
Biotech company Way Research Academy Sdn Bhd and public university Universiti Putra Malaysia (UPM) have inked a memorandum of understanding (MoU) to undertake several projects, including jointly researching on a cure for breast cancer.
During the MoU exchange ceremony held on Wednesday (Aug 3) at Universiti Putra Malaysia Teaching Hospital (HPUPM), UPM Deputy Vice-Chancellor (Research and Innovation) Prof. Dr Nazamid Saari said that the research collaboration is to cover the fields of clinical cell therapy, immunotherapy, and food technology.
He noted that UPM's collaboration with Way Research is in line with HPUPM's UPM's medical education hospital objective of intensifying and producing high-quality research.
"Among other proposed activities is a collaboration to provide medical services to patients, which will provide mutual benefits to UPM and Way Research, as well as the patients.
"In addition, this MoU also opens up opportunities for collaboration in research and learning to improve the skills and knowledge of students and staff [of UPM], especially in the field of medicine which supports HPUPM's role as a teaching hospital," he added.
In turn, Nazamid noted that the collaboration with Way Research will elevate UPM and enable it to provide the best services to its customers, as well as cooperate and network with external organisations.
Via the MoU, the biotech company and public university have also joined hands to work on Project Raya, which entails research on a cure for breast cancer.
Way Research managing director Dr Cheng Qing Shan explained that Project Raya sets out to conduct further research into the breast cancer cure the company developed, which has been shown to effectively kill cancer cells.
"Project Raya is the research we are doing together with UPM on the cure for breast cancer. It is not a treatment, but a cure. This is done by engineering immune cells found in your body to target and destroy cancer cells, which in this case applies to breast cancer.
"Currently, Project Raya is at the stage where, in the lab, the engineered immune cells have successfully cleared the cancerous cells from the breast. Now, we are moving on to the next stage, which is an animal study," he added.
Beyond Project Raya, Cheng said the company's other projects with UPM include the construction of a good manufacturing practice (GMP) lab and cellular therapy ward to provide a safe and proper environment for patients to do immunotherapy and stem cell therapy.
"Thanks to UPM, these are just teasers of the many incredible projects we are able to explore from here.
"Ultimately, we also hope that exciting projects like these can be the start of a catalyst to attract some of our brilliant minds overseas back home to Malaysia," he added.
In lieu of corporate funding, Project Raya's continued research on its cure for breast cancer is to be publicly funded.
Thus, Way Research and UPM have enabled members of the public to voluntarily enrol in the project to support their research to further develop their chimeric antigen receptor T-cell (CAR-T) immunotherapy technology, with the goal of making it accessible to all.
"Our team of researchers have been quietly working on this project for years and recently published and made some of our findings in medical journals.
"We have completed our first phase in the lab to prove that the CAR-T immunotherapy we developed effectively attacked and cleared breast cancer cells.
"We are now ready to move towards animal study and after that into human trials. Our aim is to develop this technology and make it available and accessible to all," Way Research said.
At RM1,500, eligible individuals can opt into Project Raya to enjoy benefits of protection against the full cost of future cancer cellular therapy cost of CAR-T, immunotherapy or stem cell therapy at RM20,000 as well as complimentary blood and body check-ups with cancer marker tests.
Proceeds the project sources from the public will go towards the CAR-T immunotherapy research.
Joining Way Research and UPM on Project Raya are Klinik Central SS15 and MediCap as affiliated partners.
Klinik Central SS15 and MediCap are to also support the funding of the project via the proceeds it garners from sales of their respective medical projects and services.
For more information, members of the public or interested investors may contact Way Research by calling 018-388 6180, or visiting http://www.wayresearchacademy.com.my or the company's headquarters at No.11, Jalan SS15/8A, 47500 Subang Jaya, Selangor.
Go here to read the rest:
Way Research collaborates with UPM on cure for breast cancer - The Edge Markets MY